Immunity to TCR peptides in multiple sclerosis: I. Successful immunization of patients with synthetic Vβ5.2 and Vβ6.1 CDR2 peptides

Dennis Bourdette, Ruth Whitham, Yuan K. Chou, William J. Morrison, Jeanette Atherton, Christopher Kenny, Diane Liefeld, George A. Hashim, Halina Offner, Arthur Vandenbark

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Immunization with disease-associated TCR V region peptides is an effective treatment for experimental autoimmune encephalomyelitis. Myelin basic protein-specific T cells, which induce experimental autoimmune encephalomyelitis in many animal strains, may be important in the pathogenesis of multiple sclerosis. Myelin basic protein-specific T cell clones from some multiple sclerosis patients preferentially use TCR V genes from the Vβ5.2 and Vβ6.1 families. To assess the safety and immunogenicity of TCR Vβ5.2 and Vβ6.1 peptides, we injected 11 multiple sclerosis patients with varying doses of two synthetic peptides, TCR Vβ5.239-59 and Vβ6.139-59, encompassing the CDR2 region of these V gene families. Low doses (100 to 300 μg) of peptide induced T cell immunity in 7 of 11 patients to one or both peptides. Delayed type hypersensitivity skin responses to the peptides were observed in three of seven responders, and TCR peptide-specific Ab occurred in two of seven T cell responders. Low doses of TCR peptides produced no side effects and did not cause broad spectrum immunosuppression. Synthetic TCR V region peptides can induce T cell immunity safely in humans and may prove useful in treating human autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)2510-2519
Number of pages10
JournalJournal of Immunology
Volume152
Issue number5
StatePublished - Mar 1 1994

Fingerprint

Multiple Sclerosis
Immunity
Immunization
Peptides
T-Lymphocytes
Myelin Basic Protein
Autoimmune Experimental Encephalomyelitis
Peptide T
Delayed Hypersensitivity
Immunosuppression
Genes
Autoimmune Diseases
Clone Cells
Safety
Skin
peptide V

ASJC Scopus subject areas

  • Immunology

Cite this

Immunity to TCR peptides in multiple sclerosis : I. Successful immunization of patients with synthetic Vβ5.2 and Vβ6.1 CDR2 peptides. / Bourdette, Dennis; Whitham, Ruth; Chou, Yuan K.; Morrison, William J.; Atherton, Jeanette; Kenny, Christopher; Liefeld, Diane; Hashim, George A.; Offner, Halina; Vandenbark, Arthur.

In: Journal of Immunology, Vol. 152, No. 5, 01.03.1994, p. 2510-2519.

Research output: Contribution to journalArticle

Bourdette, Dennis ; Whitham, Ruth ; Chou, Yuan K. ; Morrison, William J. ; Atherton, Jeanette ; Kenny, Christopher ; Liefeld, Diane ; Hashim, George A. ; Offner, Halina ; Vandenbark, Arthur. / Immunity to TCR peptides in multiple sclerosis : I. Successful immunization of patients with synthetic Vβ5.2 and Vβ6.1 CDR2 peptides. In: Journal of Immunology. 1994 ; Vol. 152, No. 5. pp. 2510-2519.
@article{eae6e057d7bd489b8fe43d0b54ccb8c1,
title = "Immunity to TCR peptides in multiple sclerosis: I. Successful immunization of patients with synthetic Vβ5.2 and Vβ6.1 CDR2 peptides",
abstract = "Immunization with disease-associated TCR V region peptides is an effective treatment for experimental autoimmune encephalomyelitis. Myelin basic protein-specific T cells, which induce experimental autoimmune encephalomyelitis in many animal strains, may be important in the pathogenesis of multiple sclerosis. Myelin basic protein-specific T cell clones from some multiple sclerosis patients preferentially use TCR V genes from the Vβ5.2 and Vβ6.1 families. To assess the safety and immunogenicity of TCR Vβ5.2 and Vβ6.1 peptides, we injected 11 multiple sclerosis patients with varying doses of two synthetic peptides, TCR Vβ5.239-59 and Vβ6.139-59, encompassing the CDR2 region of these V gene families. Low doses (100 to 300 μg) of peptide induced T cell immunity in 7 of 11 patients to one or both peptides. Delayed type hypersensitivity skin responses to the peptides were observed in three of seven responders, and TCR peptide-specific Ab occurred in two of seven T cell responders. Low doses of TCR peptides produced no side effects and did not cause broad spectrum immunosuppression. Synthetic TCR V region peptides can induce T cell immunity safely in humans and may prove useful in treating human autoimmune diseases.",
author = "Dennis Bourdette and Ruth Whitham and Chou, {Yuan K.} and Morrison, {William J.} and Jeanette Atherton and Christopher Kenny and Diane Liefeld and Hashim, {George A.} and Halina Offner and Arthur Vandenbark",
year = "1994",
month = "3",
day = "1",
language = "English (US)",
volume = "152",
pages = "2510--2519",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - Immunity to TCR peptides in multiple sclerosis

T2 - I. Successful immunization of patients with synthetic Vβ5.2 and Vβ6.1 CDR2 peptides

AU - Bourdette, Dennis

AU - Whitham, Ruth

AU - Chou, Yuan K.

AU - Morrison, William J.

AU - Atherton, Jeanette

AU - Kenny, Christopher

AU - Liefeld, Diane

AU - Hashim, George A.

AU - Offner, Halina

AU - Vandenbark, Arthur

PY - 1994/3/1

Y1 - 1994/3/1

N2 - Immunization with disease-associated TCR V region peptides is an effective treatment for experimental autoimmune encephalomyelitis. Myelin basic protein-specific T cells, which induce experimental autoimmune encephalomyelitis in many animal strains, may be important in the pathogenesis of multiple sclerosis. Myelin basic protein-specific T cell clones from some multiple sclerosis patients preferentially use TCR V genes from the Vβ5.2 and Vβ6.1 families. To assess the safety and immunogenicity of TCR Vβ5.2 and Vβ6.1 peptides, we injected 11 multiple sclerosis patients with varying doses of two synthetic peptides, TCR Vβ5.239-59 and Vβ6.139-59, encompassing the CDR2 region of these V gene families. Low doses (100 to 300 μg) of peptide induced T cell immunity in 7 of 11 patients to one or both peptides. Delayed type hypersensitivity skin responses to the peptides were observed in three of seven responders, and TCR peptide-specific Ab occurred in two of seven T cell responders. Low doses of TCR peptides produced no side effects and did not cause broad spectrum immunosuppression. Synthetic TCR V region peptides can induce T cell immunity safely in humans and may prove useful in treating human autoimmune diseases.

AB - Immunization with disease-associated TCR V region peptides is an effective treatment for experimental autoimmune encephalomyelitis. Myelin basic protein-specific T cells, which induce experimental autoimmune encephalomyelitis in many animal strains, may be important in the pathogenesis of multiple sclerosis. Myelin basic protein-specific T cell clones from some multiple sclerosis patients preferentially use TCR V genes from the Vβ5.2 and Vβ6.1 families. To assess the safety and immunogenicity of TCR Vβ5.2 and Vβ6.1 peptides, we injected 11 multiple sclerosis patients with varying doses of two synthetic peptides, TCR Vβ5.239-59 and Vβ6.139-59, encompassing the CDR2 region of these V gene families. Low doses (100 to 300 μg) of peptide induced T cell immunity in 7 of 11 patients to one or both peptides. Delayed type hypersensitivity skin responses to the peptides were observed in three of seven responders, and TCR peptide-specific Ab occurred in two of seven T cell responders. Low doses of TCR peptides produced no side effects and did not cause broad spectrum immunosuppression. Synthetic TCR V region peptides can induce T cell immunity safely in humans and may prove useful in treating human autoimmune diseases.

UR - http://www.scopus.com/inward/record.url?scp=0028221789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028221789&partnerID=8YFLogxK

M3 - Article

C2 - 7510746

AN - SCOPUS:0028221789

VL - 152

SP - 2510

EP - 2519

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -